SOHO 2020 | Results of a site-manufactured anti-CD19 CAR-T in nHL

Marcos de Lima, MD, of UH Cleveland Medical Center, Cleveland, OH, discusses the results of a study evaluating a second-generation anti-CD19 CAR-T construct consisting of a 4-1BB co-stimulatory domain in heavily pre-treated non-Hodgkin lymphoma (nHL) patients. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).